Items where Author is "Emery, P"

Journal article

ROBINSON, J.I., MD YUSOF, M.Y., DAVIES, V., WILD, D., MORGAN, M., TAYLOR, J.C., EL-SHERBINY, Y., MORRIS, D.L., LIU, L., RAWSTRON, A.C., BUCH, M.H., PLANT, D., CORDELL, H.J., ISAACS, J.D., BRUCE, I.N., EMERY, P., BARTON, A., VYSE, T.J., BARRETT, H., VITAL, E.M. and MORGAN, A.W., 2022. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. EBioMedicine, 86: 104343. ISSN 2352-3964

YUSOF, M.Y.M., ROBINSON, J.I., DAVIES, V., WILD, D., MORGAN, M., TAYLOR, J.C., EL-SHERBINY, Y., MORRIS, D.L., LIU, L., RAWSTRON, A.C., BUCH, M.H., PLANT, D., CORDELL, H., ISAACS, J.D., BRUCE, I.N., EMERY, P., BARTON, A., VYSE, T.J., BARRETT, J.H., VITAL, E.M. and MORGAN, A.W., 2022. OA13 Comprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. Rheumatology, 61 (S1). ISSN 1462-0332

BURSKA, A.N., EL-JAWHARI, J.J., WU, J., WAKEFIELD, R.J., MARZO-ORTEGA, H., CONAGHAN, P.G., EMERY, P., PONCHEL, F. and FREESTON, J.E., 2021. Receptor activator of nuclear factor kappa-Β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 39 (3), pp. 456-462. ISSN 0392-856X

PONCHEL, F., CHURCHMAN, S.M., EL-JAWHARI, J.J., BURSKA, A.N., CHAMBERS, P., VITAL, E.M., EL-SHERBINY, Y.M., JONES, E., CONAGHAN, P.G., GOEB, V. and EMERY, P., 2021. Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 39 (2), pp. 253-262. ISSN 0392-856X

EL‐SHERBINY, Y.M., YUSOF, M.Y.M., PSARRAS, A., HENSOR, E.M.A., KABBA, K.Z., DUTTON, K., MOHAMED, A.A.A., ELEWAUT, D., MCGONAGLE, D., TOOZE, R., DOODY, G., WITTMANN, M., EMERY, P. and VITAL, E.M., 2020. B cell tetherin: a flow‐cytometric cell‐specific assay for response to Type‐I interferon predicts clinical features and flares in SLE. Arthritis & Rheumatology, 72 (5), pp. 769-779. ISSN 2326-5191

EL-SHERBINY, Y.M., PSARRAS, A., MD YUSOF, M.Y., HENSOR, E.M.A., TOOZE, R., DOODY, G., MOHAMED, A.A.A., MCGONAGLE, D., WITTMANN, M., EMERY, P. and VITAL, E.M., 2018. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Scientific Reports, 8: 5793. ISSN 2045-2322

MD YUSOF, M.Y., PSARRAS, A., EL-SHERBINY, Y.M., HENSOR, E.M.A., DUTTON, K., UL-HASSAN, S., ZAYAT, A.S., SHALBAF, M., ALASE, A., WITTMANN, M., EMERY, P. and VITAL, E.M., 2018. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Annals of the Rheumatic Diseases, 77 (10), pp. 1432-1439. ISSN 0003-4967

LIAKOULI, V., ELIES, J., EL-SHERBINY, Y.M., SCARCIA, M., GRANT, G., ABIGNANO, G., DERRETT-SMITH, E.C., ESTEVES, F., CIPRIANI, P., EMERY, P., DENTON, C.P., GIACOMELLI, R., MAVRIA, G. and DEL GALDO, F., 2018. Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor. Annals of the Rheumatic Diseases, 77 (3), pp. 431-440. ISSN 0003-4967

MD YUSOF, M.Y., SHAW, D., EL-SHERBINY, Y.M., DUNN, E., RAWSTRON, A.C., EMERY, P. and VITAL, E.M., 2017. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 76 (11), pp. 1829-1836. ISSN 0003-4967

DAS, S., VITAL, E.M., HORTON, S., BRYER, D., EL-SHERBINY, Y., RAWSTRON, A.C., PONCHEL, F., EMERY, P. and BUCH, M.H., 2014. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Annals of the Rheumatic Diseases, 73 (5), pp. 909-912. ISSN 0003-4967

PONCHEL, F., GOËB, V., PARMAR, R., EL-SHERBINY, Y., BOISSINOT, M., EL JAWHARI, J., BURSKA, A., VITAL, E.M., HARRISON, S., CONAGHAN, P.G., HENSOR, E. and EMERY, P., 2014. An immunological biomarker to predict MTX response in early RA. Annals of the Rheumatic Diseases, 73 (11), pp. 2047-2053. ISSN 0003-4967

CHURCHMAN, S.M., CHURCH, L.D., SAVIC, S., COULTHARD, L.R., HAYWARD, B., NEDJAI, B., TURNER, M.D., MATHEWS, R.J., BAGULEY, E., HITMAN, G.A., GOOI, H.C., WOOD, P.M.D., EMERY, P. and MCDERMOTT, M.F., 2008. A novel TNFRSF1A splice mutation associated with increased NF-kappaB transcription factor activation in patients with TNF-receptor associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 67, pp. 1589-1595.

Chapter in book

MD YUSOF, M.Y., ROBINSON, J., DAVIES, V., WILD, D., MORGAN, M., TAYLOR, J., EL-SHERBINY, Y., MORRIS, D., LIU, L., RAWSTRON, A., BUCH, M.H., PLANT, D., CORDELL, H., ISAACS, J., BRUCE, I.N., EMERY, P., BARTON, A., VYSE, T., BARRETT, J., VITAL, E. and MORGAN, A., 2022. OP0190 Comprehensive genetic and functional analyses of fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. In: Scientific Abstracts oral presentations. Modern technology for precision medicine. Annals of the Rheumatic Diseases, 81 . BMJ Publishing Group, p. 126.